The global head and neck cancer drugs market size is expected
to be valued at USD 1.41 billion by 2022, as per a new report by Grand View
Research, Inc., registering a CAGR of 9.4% during the forecast period. The
market is expected to be collectively driven by development of innovative and
cost-effective treatments, numerous side effects related to radiation therapy
and chemotherapy, increased healthcare expenditure, and better government
initiatives.
As most patients suffering from head and neck cancer are diagnosed
at an advanced stage, their management is often done with a multidisciplinary
approach involving surgery, radiation therapy, chemotherapy, and immunotherapy
in the head and neck cancer therapeutics market. Major challenges faced by this
patient population are morbidity issues and poor quality of life owing to the
incapacitating effects of standard of care treatment paradigms. Anemia,
diarrhea, nausea, vomiting, joint pain, and osteoporosis are some of the main
side effects resulting from head and neck cancer treatments.
Based on recent clinical results, immunotherapies have gained
traction as a precision medicine initiative for the management of head and neck
cancer. Increased immunity and immune modulation research in cancer offers new
vulnerabilities that may be pharmacologically exploitable. Immunotherapy drugs
such as PD inhibitors, Opdivo, and Keytruda have shown superior safety and
efficacy profile in treatment of head and neck cancer. Expansion of
immunotherapies will continue moving toward rational combinations with other
first line or adjuvant therapies for effective treatment of metastatic or
recurrent head and neck cancer. EGFR and microtubule inhibitor therapeutic
classes are witnessing a fundamental shift from biologics to biosimilars.
Browse full research report on Head and Neck Cancer
Drugs/Therapeutics Market: https://www.grandviewresearch.com/industry-analysis/head-neck-cancer-drugs-therapeutics-market
Further key findings from the report
suggest:
- Market
growth will be driven by rising number of patients, increasing adoption of
immunotherapeutic drugs, and launch of new drug delivery approaches to
improve overall survival rates
- Among
EU5, Germany captured the top position in the global head and neck cancer
therapeutics market, whereas by 2022, Spain is expected to lead the
market. U.S. is expected to witness the fastest growth over the forecast
period
- Immune
checkpoint inhibitors such as Opdivo and Keytruda are gaining traction and
will continue to do so through forecast period, capturing more than 60.0%
of the market in 2022
- PD
inhibitors will capture market share from microtubule inhibitors and EGFR
inhibitors but will help expand overall franchise revenue
- Newer
immunotherapies directed against PD-1 ligands and PD-L1 proteins have
shown to be more effective with superior safety profile
- Late
stage pipeline products include checkpoint inhibitors such as Imfinzi and
Bavencio
- Key
players operating in this industry include Bristol-Myers Squibb, Merck,
Eli Lilly, and Sanofi.
Browse
request sample of this report by Grand View Research: https://www.grandviewresearch.com/industry-analysis/head-neck-cancer-drugs-therapeutics-market/request/rs1
Grand View Research has segmented the global head and neck cancer
drugs market based on therapeutic class and region:
Head and Neck Cancer Drugs Therapeutic
Class Outlook (Revenue, USD Million, 2016 - 2022)
- PD
Inhibitors
- EGFR
Inhibitors
- Microtubule
Inhibitors
Head and Neck Cancer Drugs Regional
Outlook (Revenue, USD Million, 2016 - 2022)
- U.S.
- U.K.
- France
- Germany
- Italy
- Spain
- Japan
About
Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies
ensuring relevant and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
For
more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment